Aridis is a late‑stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life‑threatening infections. mAbs represent an innovative treatment approach that harnesses the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives.
The majority of Aridis’ product candidates are derived by employing a differentiated antibody discovery platform called MabIgX. The proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life‑threatening bacterial infections, primarily hospital‑acquired pneumonia, or HAP, and ventilator‑associated pneumonia, or VAP. Three of these product candidates have exhibited promising preclinical data and clinical data are available from two completed studies and are in pivotal trial stage. The Company’s lead product candidate, AR‑301, targets the alpha toxin produced by gram‑positive bacteria Staphylococcus aureus, or S. aureus, a common pathogen associated with HAP and VAP. Aridis conducted an end‑of‑Phase 2 meeting with the U.S. Food and Drug Administration, or FDA, and initiated Phase 3 study in 1H2019.